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Background: Antiallergic effect of 20(S)-protopanaxatriol (PPT), an intestinal metabolite of ginseng sa-
ponins, was investigated in guinea pig lung mast cells and mouse bone marrow-derived mast cells
activated by a speciﬁc antigen/antibody reaction.
Methods: Increasing concentrations of PPT were pretreated 5 min prior to antigen stimulation, and
various inﬂammatory mediator releases and their relevant cellular signaling events were measured in
those cells.
Results: PPT dose-dependently reduced the release of histamine and leukotrienes in both types of mast
cells. Especially, in activated bone marrow-derived mast cells, PPT inhibited the expression of Syk pro-
tein, cytokine mRNA, cyclooxygenase-1/2, and phospholipase A2 (PLA2), as well as the activities of
various protein kinase C isoforms, mitogen-activated protein kinases, PLA2, and transcription factors
(nuclear factor-kB and activator protein-1).
Conclusion: PPT reduces the release of inﬂammatory mediators via inhibiting multiple cellular signaling
pathways comprising the Ca2þ inﬂux, protein kinase C, and PLA2, which are propagated by Syk activation
upon allergic stimulation of mast cells.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
It has been reported that Panax ginsengMeyer exerts a variety of
pharmacological effects on the immune system [1]. In the studies
with human and rodents, ginseng extracts or various ginseng
components exhibited mitogenic activity on T and B lymphocytes
[2,3], and immunomodulatory effects in a variety of diseases [4,5].
Ginseng saponin enhances the phagocytic activity of macrophage
by increasing the intracellular Ca2þ level ([Ca2þ]i)and the protein
kinase C activity [6], and ginsenoside Rh1 inhibits cyclooxygenase-
2 (COX-2) expression and nuclear factor (NF)-kB activation [7].
However, a person engaged in Korean ginseng wholesale was
recently reported to be suffering from occupational asthma [8].
In the inﬂammatory and allergic responses, protopanaxadiol
Rb1 inhibits histamine release and leukotrienes (LTs) in guinea pig
lung mast cells (GPMCs) activated by speciﬁc antigen/antibodygy, College of Medicine, Hanyang
gy, School of Medicine, Sungkyunk
), changholee57@gmail.com (C.H. L
erms of the Creative Commons At
ribution, and reproduction in any
ght  2014, The Korean Society ofreaction [9]. Ginseng ameliorates chronic histopathologic changes
in murine asthma [10]. Ginsan, a polysaccharide derived from
P. ginseng, also has tumoricidal activities [11], antiseptic activity
[12], and antiasthmatic effects in a mouse OVA (ovalbumin)-
induced asthma model [13].
A variety of ginseng saponin metabolites are formed by intes-
tinal bacteria when total ginseng extracts or total ginseng saponin
is administered orally to a human or rat, respectively, and absorbed
into the systemic circulation [14,15], and then their metabolites
including nonsugar moieties of ginsenosides (aglycones) are
detected in blood and in urine. Compound K [16] and Rh2 [17]
among various ginseng metabolites have potent inhibitory activity
on b-hexosaminidase release from RBL-2H3 cells.
Mast cells are well known as major effector cells for immuno-
globulin (Ig) E-mediated immediate hypersensitivity and chronic
allergic reactions such as asthma. Antigen-speciﬁc IgE bound to theUniversity, 222 Wangsimni-ro, Seongdong-gu, Seoul 133-791, Korea.
wan University, 2066 Seobu-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-746, Korea.
ee).
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ters the multivalent antigen, and then the cells are activated.
Activated mast cells secrete preformed mediators [histamine,
tryptase, chymase, tumor necrosis factor (TNF)a, and other pro-
teins] as well as newly synthesized proinﬂammatory mediators
such as prostaglandin D2, LTs, cytokines, and chemokines [18e21].
These mediators have been postulated to be responsible for airway
inﬂammation and remodeling in allergic asthma [19,22].
Although 20(S)-dihydroprotopanaxadiol and 20(S)-dihy-
droprotopanaxatriol have distinctive immunological responses
[23,24], the effects of 20(S)-protopanaxatriol (PPT, Fig. 1A), one of
the ginseng saponin metabolites formed by human intestinal bac-
teria, on the inﬂammatory mediator release during mast cell acti-
vation, which is a well-known event in allergic asthma, has notFig. 1. Effects of 20(S)-protopanaxatriol (PPT) on the release of mediators or mRNA expressio
sensitized with anti-ovalbumin (OVA) antibody and then stimulated with OVA challenge.
challenged with anti-dinitrophenyl immunoglobulin E antibody and human serum albumi
(10mM, 50mM, or 100mM) was pretreated 5 min prior to the OVA challenge. (A) Chemical str
panel) and BMMCs (right panel). Histamine release (%) was expressed as the percentage of
Expressions of cytokine mRNA in activated BMMCs. The total number of experiments were
challenge. 1) Numbers below the bands indicate the ratio of band intensity of each band vebeen reported yet. Therefore, we examined the effects of PPT on the
release of inﬂammatory mediators from the guinea pig lung mast
cells (GPMCs) and mouse bone marrow-derived mast cells
(BMMCs) activated by a speciﬁc antigen/antibody reaction to
determine the role of ginseng intestinal metabolites of orally
administered ginseng extract.
2. Materials and methods
2.1. Animals
Female Hartley guinea pigs weighing 200e250 g and female
BALB/c mice weighing 20 g (age 8 weeks) were purchased from
Samtako BioKorea (Osan, Korea) and maintained in speciﬁcn of cytokines in activated mast cells. Guinea pig mast cells (GPMCs; 4  105 cells) were
Mouse bone marrow-derived mast cells (BMMCs; 1  106 cells) were sensitized and
nedinitrophenyl (HSA-DNP), respectively, as described in Materials and methods. PPT
ucture of PPT. (B) Amounts of histamine and leukotrienes (LTs) released in GPMCs (left
the total histamine in nonstimulated cells. LTs were determined as pg/L  106 cells. (C)
eight (n ¼ 8). ***, p < 0.001 versus control (Con); þ p < 0.05; þþþ p < 0.05 versus OVA
rsus that of control and GAPDH mRNA.
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housed in accordance with the guideline from the Association for
the Assessment and Accreditation of Laboratory Animal Care
(AAALAC), and all protocols were approved by the Institutional
Review Board and conducted in the Laboratory Animal Research
Center of Sungkyunkwan University, Suwon, Korea.
2.2. Reagents
OVA (fraction V), collagenase (type I), elastase (type I, porcine
pancreatic), human serum albuminedintrophenyl (HSA-DNP),
Fluo-3 AM, and percoll were purchased from Sigma-Aldrich
Chemical Co (St Louis, MO, USA); leukotriene immunoassay kit and
[3H]arachidonic acid were purchased from PerkinElmer (Waltham,
MA, USA); and gelatin was purchased from Difco Laboratories
(Detroit, MI, USA). PPT (molecular weight, 476.7) was prepared by
the chemical modiﬁcation of ginseng saponin with periodic acid as
described previously [25]. Its structure is shown in Fig. 1A. Other
chemicals and reagents used in this experiment were of the best
grade.
The PPT was dissolved in 50mM stock solution in dimethyl
sulfoxide (DMSO), and diluted prior to use. The percentage (%) of
DMSO in experimental solution or media was 0.01%, 0.02%, and
0.04% for 10mM, 50mM, or 100mM PPT, respectively. These per-
centages of DMSO did not affect release of mediators (data not
shown). The concentration of PPT was chosen in preliminary
experiments.
2.3. Immunization and preparation of anti-OVA antibody
Ten outbred female guinea pigs were immunized by injecting a
mixture of 50 mg/200 mL OVA and complete Freund’s adjuvant into a
foot pad. After 1 week, 100 mg/200 mL OVA was injected intrader-
mally at one side of the back of the animals and 200 mg/200 mL of
OVA at the other side of the back of the animals. One week later,
mice were sacriﬁced for getting sera, and the sera were kept in
aliquots at 70C until use [26]. To separate IgG1 antibody from
sera, guinea pig serumwas applied to anti-IgG2 afﬁnity column and
the column was washed with 0.1M citric acid (pH 2.1). IgG1 passed
through and it was concentrated under pressure for the experi-
ment. The titers of anti-OVA antibody were in the range 1,600e
3,200 using passive cutaneous anaphylaxis method [26]. The sera
were used for preparing the sensitized GPMCs.
2.4. GPMC preparation
GPMCs were isolated and puriﬁed as reported previously [26].
Brieﬂy, each lung isolated from eight unsensitized guinea pigs was
perfused with 50 mL of the modiﬁed Tyrode’s buffer (TGCM buffer:
137mM NaCl, 0.36mM NaH2PO4, 2.6mM KCl, 1mM CaCl2, 1.5mM
MgCl2, 119mM NaHCO3, 5.5mM glucose, 1 g/L gelatin, pH 7.4). After
removing large airways and blood vessels, the lungs were chopped
with a McIlwain tissue chopper (The Mickle Laboratory Engineer-
ing Co., Gomshall, Surrey, UK). Pooled tissue was treated three
times with collagenase (125 U/g tissue) and elastase (5 U/g tissue)
for 15 min, 15 min, and 25 min. The freed cells were separated by
ﬁltrating through mesh and Nytex mesh (100 mm). The cells were
washed with Tyrode’s buffer without CaCl2 and MgCl2 containing
gelatin (TG buffer) and laid over gradients consisting of 10 mL
Percoll (density, 1.045 g/mL), and then centrifuged at 800  g for
20 min. Pelleted cells containing mast cells (w3.5  108 cells/
gradient) were resuspended in TG buffer and applied in discon-
tinuous Percoll (1 mL) density gradients (density gradients: 1.06 g/
mL, 1.07 g/mL, 1.08 g/mL, 1.09 g/mL, and 1.10 g/mL) for centrifuga-
tion at 800  g for 20 min. The mast cells were collected with thehighest purity and number (1e2107) from the bands between the
1.09 g/mL and 1.10 g/mL densities. This gradient bandwas removed,
washed with TGCM buffer. The partially puriﬁed mast cells
were identiﬁed with Alcian blue staining, and the viability was
assessed using trypan blue exclusion assay. The purity of the mast
cell preparation was 80e90% and the cell viability was consistently
> 98%.
2.5. Culture of BMMCs
Bonemarrow cells were ﬂushed from femurs and tibias of BALB/
c mice. RBC was lysed using 0.1M NH4Cl and remaining cells were
washed, resuspended, and cultured for 5 weeks in RPMI-1640
supplemented with 10% heat-inactivated fetal bovine serum and
50%WEHI-3B conditionedmedia, which contains interleukin (IL)-3.
The media were changed twice per week. BMMCs were conﬁrmed
by May-Grünwald Giemsa staining [27]. Brieﬂy, BMMCs were
collected onto object glasses by cytospin (400  g, 3 min). Cells
were ﬁxed in methanol for 2e3 min and then stained with May-
Grünwald solution for 15 min, followed by Giemsa solution for
10 min and by washing steps in H2O. The purity of BMMCs was >
99%.
2.6. Sensitization and measurements of mediator release in the
activated mast cells
As described previously [26], the partially puriﬁed GPMCs
(4  105) were sensitized with anti-OVA antibody (1 106 cells/mL
antibody) for 45 min at 37C in a shaking water bath. The cells were
then washed, suspended in TGCM buffer, and challenged with
1.0 mg/mL OVA for 10 min or 20 min for histamine and LT release,
respectively. After terminating the reaction on ice bath, superna-
tant was taken for measuring the amounts of the released hista-
mine and LTs.
BMMCs (1  106 cells) were sensitized with anti-DNP IgE anti-
body (0.1 mg/mL) overnight at 37C. The cells were washed, and
then challenged with 1.0 ng/mL HSA-NP) for time periods indicated
(optimal time, 6 h) at 37C in Tyrode’s buffer [27].
In all experiments, optimal time and concentration for activa-
tion of GPMCs and BMMCs were ﬁrst determined in preliminary
experiments, and both types of mast cells were treated with PPT
(10mM, 50mM, or 100mM) 5 min prior to the antigen challenge.
2.7. Histamine assay
Amounts of histamine release in each supernatant obtained
after activation of GPMCs or BMMCs were quantiﬁed by the auto-
mated ﬂuorometric analyzer (with dialysis; Series 300 Analyzer;
Astoria Clackamas, OR, USA). The detection limit of this assay is
approximately 5 ng/mL of histamine. Amounts of histamine release
were expressed as the percentage of the total histamine in non-
stimulated cells [26].
2.8. LT immunoassay
The amounts of LTs in each supernatant obtained fromGPMCs or
BMMCs were determined using an enzyme immunoassay kit
(Cayman Chemical, Ann Arbor, MI, USA) according to the manu-
facturer’s instructions. Brieﬂy, 50 mL samples were incubated with
anti-LT antiserum (diluted 1:120) and acetylcholinesterase-linked
LTs (diluted 1:120) in wells that were coated with mouse mono-
clonal antibodies for 18 h at room temperature. After rinsing with
washing buffer, color was developed using Ellman’s reagent, and
the plates were read at 412 nm with a spectrophotometer. The
concentrations of LTs were then calculated using standard curves
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the Cayman Chemical website (http://www.caymanchem.com/
app/template/analysis%2CEIA.vm/a/z).
2.9. Reverse transcriptionepolymerase chain reaction
Total cellular RNAwas isolated from BMMCs (1106 cells) using
Trizol reagent. Reverse transcriptionepolymerase chain reaction
(RT-PCR) was performed in a ﬁnal volume of 50 mL using a amﬁR-
ivert one-step RT-PCR kit (GenDEPOT, Barker, TX, USA) in an auto-
mated thermal cycler (BIOER Technology, Hangzhou, China). PCR
assays were performed for 35 cycles. Each cycle consisted of the
following steps: denaturation at 94C for 30 s, annealing at 56C for
45 s, and extension at 72C for 1 min. PCR products were analyzed
using 1.0% agarose gel containing ethidium bromide.
The primer sequences used were as follows: IL-1b sense, 50-TGA
AGGGCT GCT TCC AAA CCT TTGACC-30; IL-1b antisense, 50-TGT CCA
TTGAGG TGGAGAGCT TTC AGG-30; IL-4 sense, 50-TCG GCATTT TGA
ACG AGG TC-30; IL-4 antisense, 50-GAA AAG CCC GAA AGA GTC TC-
30; IL-5 sense, 50-ATG GAG ATT CCC ATG AGC AC-30; IL-5 antisense,
50-GTC TCT CCT CGC CAC ACT TC-30; IL-6 sense, 50-TGG AGT CAC
AGA AGG AGT GGC TAA G-30; IL-6 antisense, 50-TCT GAC CAC AGT
GAG GAA TGT CCA C-30; IL-8 sense, 50-CAA ACC TTT CCA CCC CAA
AT-30; IL-8 antisense, 50-ATT GCA TCT GGC AAC CCT AC-30; IL-10
sense, 50-CAT GGG TCT TGG GAAGAGAA-30; IL-10 antisense, 50-CAT
TCC CAG AGG AAT TGC AT-30; IL-13 sense, 50-CAG CTC CCT GGT TCT
CTC AC-30; IL-13 antisense, 50-CCA CAC TCC ATA CCA TGC TG-30;
TNFa sense, 50-TTA TCT CTC AGC TCC ACG CC-30; TNFa antisense, 50-
TGC GCA CTG AAA GCA TGA TC-30; interferon-g sense, 50-GCT CTG
AGA CAA TGA ACG CT-3; interferon-g antisense, 50-AAA GAG ATA
ATC TGG CTG TGC-30; GAPDH sense, 50-GAT GCA GGG ATG ATG TTC
TG-30; and GAPDH antisense, 50-GTG AAG GTC GGT AAC GG-30 [28].
2.10. Measurements of the intracellular Ca2þ level in the activated
mast cells
The sensitized GPMCs (4  105 cells) or BMMCs (4  105 cells)
were incubated for 30 min after adding Fluo-3 AM (5mM) and placed
on a glass slide treated with poly-L-lysine, and then OVA (1.0 mg/mL)
for GPMCs or HSA-DNP for BMMCswasﬂowedout on a glass slide for
stimulation. The cellswere treatedwith PPT (10mM,50mM,or 100mM)
5min prior to each antigen challenge (OVA or HSA-DNP). The [Ca2þ]i
of both types of mast cells were monitored for 10 min after each
antigen stimulation using a confocal laser scanningmicroscopy (Leica
TCS NT Confocal Microscopy, Leica, Heidelberg, Germany) [24,26].
[Ca2þ]i was estimated with LSM500 software (Mitutoyo America
Corporation, Aurora, IL, USA). Relative intensity (RI) indicated the
ratio of optical ﬂuorescence density versus the control (RI ¼ 1).
2.11. Immunoprecipitation for Syk
Immunoprecipitation of Syk protein was performed according
to method provided previously [29]. Brieﬂy, agarose conjugate
(50 mL) was washed twice with washing buffer (PBS, pH 7.4),
centrifuged for 10 s at 12,000  g at room temperature and then
resuspended in washing buffer. Agarose conjugate was added to
10 ml anti-Syk antibody (Upstate, Lake Placid, NY, USA), incubated
for 60 min at room temperature with gentle mixing, and then
centrifuged at 3,000  g for 2 min at 4C. Samples were washed
with 1 mL washing buffer, centrifuged at 3,000 g for 2 min at 4C,
and this step was repeated at least twice. Cell lysates (200 mg pro-
tein) were added to agarose conjugate-bound antibody, and incu-
bated overnight at 4C with gentle mixing. Immunoprecipitated
complexes were washed with washing buffer and centrifuged at
3,000  g for 2 min at 4C. Pellets were washed with 1 mL washingbuffer and centrifuged at 3,000  g for 2 min at 4C. This step was
repeated at least three times. The pellet was resuspended with 25e
100 mL Laemmli sample buffer [0.125M Tris HCl (pH 6.8), 4% SDS,
20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue].
Samples were heated at 95C for 5 min, centrifuged for 30 s at
12,000  g at room temperature, and then the supernatants
collected (immunoprecipitation sample).
Immunoprecipitation samples were stored in sample buffer
at 70C until assay. Samples and molecular weight standards
were run with known concentrations on sodium dodecyl sulfatee
polyacrylamide gel electrophoresis, transferred to nitrocellulose
membrane, and immunoblotting performed.
2.12. Measurements of protein kinase C activity in the activated
GPMCs
The sensitized GPMCs (1  106 cells) were preincubated in the
presence of histone (0.2 mg/mL), phosphatidylserine (40 mg/mL),
and [g-32P] ATP (1mM) at 30C for 5 min. The cells were treatedwith
100mM PPT 5 min prior to OVA stimulation. The changes in the
protein kinase C (PKC) activity in mast cells were measured at
10 min after 1.0 g/mL OVA stimulation. The reactionwas stopped by
adding 1 mL of 10% TCA at 4C for 30 min. The reaction mixtures
were ﬁltered through a glass ﬁber disk (GF/B; Whatman, Maid-
stone, Kent, UK) to remove unreacted [g-32P] ATP, and then were
washed four times with 20mM tetrasodium pyrophosphate and
once with absolute ethanol. After drying the glass ﬁber disk,
radioactivity was measured with a liquid scintillation counter [26].
2.13. Measurements of phospholipase A2 activity in the activated
GPMCs
GPMCs (1  106 cells) were preincubated with [3H] arachidonic
acid (1 mCi) at 37C for 1 h. The labeledmast cells werewashed twice
and resuspended in TGCM buffer. The cells were sensitized by anti-
OVAantibody (1106 cells/mL antibody) at 37C for 45min and then
stimulated with 1.0 mg/mL OVA at 37C for 10 min, and the reaction
were stoppedby theadditionof 1N formic acid. The cellswere treated
with 100mM PPT 5 min prior to the OVA challenge. The mast cells
were then centrifuged at 800  g for 10 min. Reactivities released in
supernatant were counted by adding Aquasol (PerkinElmer,
Boston, MA, USA) for liquid scintillation spectrometry [30].
2.14. Immunoblotting for signaling molecules in the activated mast
cells
The activated GPMCs (1  106 cells) or BMMCs (1  106 cells)
were homogenized in lysis buffer [10mM HEPES (pH 7.9), 10mM
KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM DTT, 0.5mM PMSF, 2.0 mg/mL
aprotinin, 2.0 mg/mL leupeptin], and allowed to swell on ice for
10 min. Cell lysates (mg) were subjected to 8% or 10% sodium
dodecyl sulfateepolyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose membranes (Amersham Bioscience, Amer-
sham, Buckinghamshire, UK). Membranes were washed with PBS
containing 0.1% Tween 20 (PBST), and then blocked for 1 h in PBST
containing 5% skim milk. After the membranes were washed with
PBST, they were incubated for 60 min at room temperature with
antibodies against Syk, PKC isotypes (a, bI, bII), extracellular signal-
regulated kinase (ERK), c-jun N-terminal kinase (JNK), p38, COX-1/
2, secreted phospholipase A2 (PLA2), actin (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA), as well as p-PKCs, p-ERK, p-JNK,
p-p38, diluted with PBST (1:1,000). Membranes were washed with
PBST and treated with horseradish peroxidase-conjugated rabbit
anti-goat IgG (diluted to 1:5,000e1:10,000; Zymed Laboratory Inc.,
San Francisco, CA, USA) in PBST for 60 min. After washing, the
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solution (Amersham Biosciences) [28].
2.15. Electrophoretic mobility shift assay
To prepare nuclear extracts, BMMCs (1 106 cells) were washed
twice with ice-cold PBS and resuspended in 1 mL ice-cold buffer A
(10mM Hepes/KOH pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.5mM DTT,
0.2mM PMSF, 1 mg/mL leupeptin, and 1 mg/mL aprotinin. After in-
cubation on ice for 15 min, the cells were lysed by adding Nonidet
P40 (10 mL 10% Nonidet P40, to a ﬁnal concentration of 0.625%, v/v)
and immediately vortexed for 10 s. Nuclei were harvested by
centrifugation at 20,000  g for 1 min and resuspended in 40 mL
ice-cold buffer C (20mM Hepes/KOH pH 7.9, 0.42M NaCl, 1.5mM
MgCl2, 0.2mM EDTA, 0.5mM DTT, 25% glycerol, 0.2mM PMSF, 1 mg/
mL leupeptin, and 1 mg/mL aprotinin). After incubation at 4C for
20 min on a shaking platform, the nuclei were clariﬁed by centri-
fugation at 15,000 g for 10 min. The supernatant (nuclear extract)
was then transferred to a new tube and quantiﬁed using Bradford’s
method. Nuclear extracts were stored at 70C until required [28].
Ten microliters of a mixture of NF-kB (50-AGT TGA GGG GAC TTT
CCC AGG C-30, 30-TCA ACT CCC CTG AAA GGG TCC G-50) or activator
protein-1 (AP-1; 50-CGC TTG ATGAGT CAG CCG GAA-30, 30-GCGAAC
TAC TCA GTC GGC CTT-50) oligonucleotide (1.75mM), T4 poly-
nucleotide kinase 10  buffer, [a-32P]ATP (10 mCi; 3,000 Ci/mmol),
nuclease-free water, and T4 polynucleotide kinase (5e10 U/mL)
were incubated at 37C for 30 min. The reaction was stopped by
adding 1 mL EDTA (0.5M). After adding 89 mL Tris-EDTA buffer
(10mM Tris-HCl pH 8.0, 1mM EDTA), unincorporated nucleotides
were separated from the DNA probe by G-25 spin column chro-
matography. The nuclear extract and gel shift binding 5  buffer
[20% glycerol, 5mMMgCl2, 2.5mM EDTA, 2.5mMDTT, 250mMNaCl,
50mM Tris-HCl pH 7.5, and 0.25 mg/mL poly(dI-dC)] were incu-
bated at room temperature for 10 min, and then 20e30 fmol of 32P-
labeled NF-kB or AP-1 oligonucleotide was added and incubated at
room temperature for 20 min. After stopping the reaction, 1 mL of
10  gel loading buffer was added to each reaction. Reaction mix-
tures were electrophoresed on 6% polyacrylamide gels, and the gels
were analyzed using FLA-2000 (Fujiﬁlm, Tokyo, Japan).
2.16. Statistical analysis
Experimental data were expressed as mean  standard error of
the mean. An analysis of variance (ANOVA) was used for statistical
analysis. Signiﬁcance between control and experimental groups
was determined by Scheffe’s posthoc test using SPSS version 21
(SPSS Inc., Chicago, IL, USA). The bands for RT-PCR, western blot and
electrophoretic mobility shift assay are representative of four in-
dependent experiment (n ¼ 4). A p value of 0.05 was regarded as
statistically signiﬁcant.
3. Results
3.1. Effect of PPT on the release of histamine and LTs in the activated
GPMCs and BMMCs
It is well known that histamine and LTs are released from mast
cells when activated by antigen/antibody reaction. Two types of
mast cells, GPMCs and mouse bone marrow-derived mast cells
BMMCs were used for this study since commercially available an-
tibodies for guinea pigs have certain limitations for investigating
signaling molecules related to allergic responses. In addition, it is
known that mast cells are different in their function, depending on
their location in the types of organs (lung, bone marrow, etc.) and
species (guinea pigs, mice, etc.).In order to determine whether PPT causes some effects on the
release of inﬂammatory mediators (histamine and LTs) in quiescent
GPMCs or BMMCs, unsensitized each types of mast cells pretreated
with various concentrations of PPT (5mM, 10mM, 50mM, 100mM, or
300mM) for 5 min were challenged by OVA (1.0 mg/mL), or both
types of mast cells sensitized with anti-OVA antibody were chal-
lenged with various concentrations of PPT (5mM, 10mM, 50mM,
100mM, or 300mM) for 30 min or 1 h. It was conﬁrmed that PPT
itself did not cause any effects on the mediator releases if not an-
tigen/antibody stimulation (data not shown).
Effects of PPT on the mediator release were examined in GPMCs
or BMMCs activated by each speciﬁc antigen/antibody reaction. In
the activated GPMCs, PPT pretreatment (10mM, 50mM, or 100mM)
dose-dependently inhibited histamine release by 5.4%, 41.4%, and
60.5%, respectively (28.6  0.05% for 10mM; 17.7  0.34% for 50mM;
and 11.9  0.25% for 100mM PPT), compared with that of OVA
stimulation (30.2  0.72%; Fig. 1B, left panel). In the activated
BMMCs, histamine release was inhibited by PPT pretreatment by
7.9%, 37.6%, and 70.1% (30.6  0.07% for 10mM; 20.7  0.35% for
50mM; and 9.9  0.26% for 100mM PPT), compared with that of OVA
challenge (33.2  0.76%; Fig. 1B, right panel).
Patterns of LT secretion in the activated GPMCs or BMMCs were
similar to those of histamine release in both types of mast cells. PPT
(10mM, 50mM, or 100mM) inhibited LTs release by 3.4%, 27.6% and
55.4%, respectively, in activated GPMCs (6.5  0.04  102 pg/mL for
10mMPPT; 4.90.39102 pg/mL for 50mMPPT; 3.0 0.09102 pg/
mL for 100mM PPT), compared with that of OVA challenge
(6.8 0.13102 pg/mL; Fig.1B, left panel). In activated BMMCs, PPT
inhibited LTs release by 4.7%, 21.9%, and 45.7% (4.1  0.06  103 pg/
mL for 10mM PPT; 3.3  0.11  103 pg/mL for 50mM PPT; and
2.3  0.12  103 pg/mL for 100mM PPT), compared with that of OVA
challenge (4.3  0.07  103 pg/mL; Fig. 1B, right panel).
Histamine and LTs release in the unstimulated GPMCs or
BMMCs were 1.3  0.27% and 4.3  0.50%, and 1.3  0.09  102 pg/
mL and 0.2  0.00  103 pg/mL, respectively. Total amounts of
histamine in the unstimulated GPMCs or BMMCs were
2,356  70.7 ng/4  105 cells and 758  31.3 ng/L  106 cells,
respectively.
3.2. Effect of PPT on the expressions of cytokine mRNA in activated
BMMCs
In addition to the release of histamine and LTs, mast cells secrete
various types of cytokines, particularly inﬂammatory cytokines (IL-
1b, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, TNF-a, and interferon-g) [20].
Thus, whether the mRNA levels of each cytokines were altered by
PPT was examined in the activated BMMCs. PPT pretreatment
(10mM, 50mM, or 100mM) inhibited the expressions of all cytokines’
mRNA in dose-dependent manner, except IL-10 mRNA expression,
which was increased in the activated BMMCs (Fig. 1C).
3.3. Effect of PPT on [Ca2þ]i in activated GPMCs and BMMCs
Increments of [Ca2þ]i are crucial for degranulation in activated
mast cells [20,26,31,32]. In activated GPMCs, changes in the [Ca2þ]i
were monitored for 10 min after OVA challenge (data shown only
for 5 min). [Ca2þ]i reached the maximum level (approximately 1.9
folds of basal level) at 3 min and was maintained until 10 min. PPT
pretreatment (100mM) strongly prevented the OVA-induced rise in
[Ca2þ]i and kept it at the basal level (Fig. 2A). In the activated
BMMCs, [Ca2þ]i increased steadily, reached the maximum at 5 min
(approximately 1.9 folds of basal level), and was maintained until
10 min (data shown only for 5 min). PPT (10mM, 50mM, or 100mM)
pretreatment signiﬁcantly suppressed [Ca2þ]i (Fig. 2B). Especially,
PPT inhibited [Ca2þ]i in activated GPMCs more prominently than in
Fig. 2. Effects of 20(S)-protopanaxatriol (PPT) on the intracellular Ca2þ level ([Ca2þ]i)
and expression of Syk kinase protein in activated mast cells. The sensitized guinea pig
mast cells (GPMCs) or mouse bone marrow-derived mast cells (BMMCs; 4  105) were
incubated for 30 min after adding Fluo-3 AM (5mM) and ﬁxed on a glass slide treated
with poly-L-lysine, and then ovalbumin (OVA; 1.0 mg/mL) or human serum albumine
dinitrophenyl (HSA-DNP), respectively, was ﬂowed out on a glass slide for stimulation.
The [Ca2þ]i was monitored for 10 min using confocal microscopy, and Syk protein
expression after immunoprecipitation was determined with western blot, as described
in Materials and methods. PPT (10mM, 50mM, or 100mM) was pretreated 5 min prior to
the OVA challenge. (A and B) [Ca2þ]i in (A) GPMCs and (B) BMMCs. In total there were
eight experiments. **p < 0.01; ***p < 0.001 versus control; þþ, p < 0.01; þþþ, p < 0.001
versus OVA or HSA-DNP challenge. C, Syk protein. 1) Numbers below the bands indicate
the ratio of band intensity of each band versus that of control and actin. The data are
representative of four independent experiments.
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ities of PKC and PLA2 in GPMCs were tested only at the highest
concentration of PPT since it was hard to purify GPMCs and thus
only limited GPMCs were available.
3.4. Effect of PPT on the expression of Syk protein in the activated
BMMCs
As PPT reduced the [Ca2þ]i elevated in IgE-induced mast cell
activation, it was examined whether Syk kinase, an upstreamsignaling molecule of [Ca2þ]i inﬂux was affected by PPT pretreat-
ment. PPT (10mM, 50mM, or 100mM) signiﬁcantly reduced the
increased level of expression of Syk kinase in BMMCs when acti-
vated by antigen/antibody stimulation (Fig. 2C).
3.5. Effect of PPT on the PKC activity in the activated GPMCs and
BMMCs
It has been reported that PKC is activated by an elevation of
[Ca2þ]i level in the stimulated B cells and mast cells [26,31]. The
changes in the PKC activity in both types of mast cells were
measured after stimulation. The activity of PKC was enhanced in
OVA-challenged GPMCs by 59.3%. The OVA-induced increment in
PKC activity was remarkably counteracted by 100mM PPT (Fig. 3A).
The Ca2þ-dependent PKC isoforms (PKCa, bI, and bII) are acti-
vated in mast cells, and then the activated PKC isoforms regulate
mitogen-activated protein (MAP) kinases [18,33]. Fig. 3B showed
that PKC isoforms (a, bI, bII) are phosphorylated by antigen/anti-
body reaction in BMMCs, and PPT (10mM, 50mM, or 100mM)
inhibited the phosphorylation of PKC isoforms in the activated
BMMCs. In addition, we observed the phosphorylations of ERK, JNK,
and p38 MAP kinases in activated BMMCs. PPT (10mM, 50mM, or
100mM) reduced the augmented phosphorylation of MAP kinases in
activated BMMCs (Fig. 3C).
3.6. Effect of PPT on the PLA2 activity in activated GPMCs and
BMMCs
The changes in the PLA2 activity in GPMCs were assayed after
OVA stimulation. OVA increased the PLA2 activity by 38% of basal
activity in stimulated GPMCs. The OVA-induced increment in the
enzyme activity was decreased by 30.2% when the cells were pre-
treated with 100mM PPT (Fig. 4A).
In GPMCs and BMMCs, the level of protein expression of PLA2
was enhanced upon stimulation with OVA challenge (Fig. 4B). PPT
pretreatment (10mM, 50mM, or 100mM) dose-dependently reduced
the PLA2 expression in each type of activated mast cells.
3.7. Effect of PPT on the activity of COX-1/2 in the activated BMMCs
It is well known that prostaglandins (PGs) are produced by the
actions of both constitutive enzyme COX-1 and inducible enzyme
COX-2. In mast cells, certain amount of COX-1 is expressed and
COX-2 is induced by the antigen/antibody stimulation [34,35]. It
was also observed that expression of COX-2 was enhanced in
activated BMMCs, but COX-1 was not affected (Fig. 4C). PPT
decreased dose-dependently only the induced level of COX-2
expression by antigen stimulation, but not that of COX-1 expression
(Fig. 4C).
3.8. Effect of PPT on the activity of transcription factors in the
activated BMMCs
NF-kB and AP-1 are transcription factors controlling the ex-
pressions of inﬂammatory cytokines in mast cells. These tran-
scription factors were upregulated in the activated BMMCs. PPT
(10mM, 50mM, or 100mM) inhibited the DNA binding activities of
transcription factors in a dose-dependent manner (Fig. 4D).
4. Discussion
Mast cells participate in the induction of innate and adaptive
immune responses [20,36]. Mast cells inﬂuence both health and
diseases, such as allergy, arthritis, autoimmunity, and neoplasia, by
releasing and producing a variety of mediators [20,26].
Fig. 3. Effects of 20(S)-protopanaxatriol (PPT) on the activities of protein kinase C (PKC) or mitogen-activated protein (MAP) kinases in activated mast cells. The sensitized guinea
pig mast cells (GPMCs; 1  106 cells) incorporated with [g-32P]ATP (1mM) and sensitized mouse bone marrow-derived mast cells (BMMCs; 1  106 cells) were stimulated by each
antigen/antibody reaction as described in Materials and methods. PPT (10mM, 50mM, or 100mM) was pretreated 5 min prior to the antigen challenge. The PKC activity was measured
by the phosphorylated protein at 30 min after OVA challenge, and activities of PKC isoforms and MAP kinases were determined using western blot. (A) PKC activity in GPMCs. The
data are expressed as mean  standard error of the mean (n ¼ 8). *** p < 0.001 versus control (Con). þþþ p < 0.001 versus OVA challenge. (B and C) The phosphorylation of PKCs and
MAP kinases in BMMCs. 1) Numbers below the bands indicate the ratio of band intensity of each band versus those of control and total protein. The data are representative of four
independent experiments. ERK, extracellular signal-regulated kinase; JNK, c-jun N-terminal kinase; OVA, ovalbumin; HSA-DNP, human serum albuminedinitrophenyl.
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saccharide components of ginseng, respectively, have many bio-
logical activities including inﬂammatory responses in mast cells as
well as allergic inﬂammation [7,16,37]. Herein, we demonstrated
that PPT, one of the ginseng saponin metabolites formed by human
intestinal bacteria and of nonsugar moiety of ginsenoside (agly-
cone), reduced the release of mediators by [Ca2þ]i level, PLA2, PKC,
and NF-kB/AP-1 activities which are downstream signals regulated
by Syk kinase in FceRI-mediated mast cell activation.
The antigen-mediated activation of mast cells via engagement
of the IgE bound to FceRI receptor represents an initial event in
the development of type I hypersensitivity reaction, and results
in degranulation, with the release of various inﬂammatory me-
diators, such as histamine, LTs, and cytokines [20,26,32]. That is,
IgE-mediated signaling pathways lead to the release of pre-
formed mediators (histamine, tryptase, etc.) by PKC activity that
is accompanied by Ca2þ inﬂux, which is critical for the down-
stream propagation signals by Syk-mediated phosphorylation
and the activation of PLCg or PLD enzyme [18,20,38,39]. There-
fore, we examined the effects of PPT on the well-known signaling
pathways in mediator release from IgE-mediated mast cell acti-
vation. Our data (Figs. 1B, 2, 3A, 3B) suggest that PPT reduceshistamine release via the inhibition of PKC activity caused by
blocking of the rise in [Ca2þ]i through regulating Syk in FceRI-
mediated mast cell activations. Similarly, it was reported that
ginsenoside Rb1, which has a sugar moiety in its structure,
inhibited mediator release in activated GPMCs [9]. However,
there has been a report that ginseng saponin enhanced [Ca2þ]i
and PKC activity in macrophage activation [6]. This may be due to
the cell types or the sort of ginsenoside components used in each
separate experiment.
Rapid hydrolysis of phospholipids in mast cell membrane also
occurs through the activation of cytosolic phospholipase A2 (cPLA2)
in IgE-mediated signaling pathways. Hydrolyzed phospholipids
were converted into arachidonic acids. Then, enzymes such as COX-
1/2 or 5-lipoxigenase (LOX) convert them into PGs and LTs,
respectively, which affects the early phase of allergic responses in
mast cells [34,35,38,40,41]. A rise in [Ca2þ]i is necessary for trans-
location of cPLA2 to the cell membrane in FceRI-mediated mast cell
activation [18,42]. It has been reported that ginsenoside Rh1
inhibited COX-2 [7]. Our data (Figs. 1B, 2A, 2B, 4AeC) suggest that
PPT-mediated reduction in [Ca2þ]i leads to the decrements in pro-
duction of LTs via inhibiting the activities of cPLA2 and most likely
LOX during mast cell activations. In addition, we observed that PPT
Fig. 4. Effects of 20(S)-protopanaxatriol (PPT) on the phospholipase A2 (PLA2) activity or expression of cyclooxygenase (COX)-1/2, and the DNA binding activities of transcription
factors, nuclear factor (NF)-kB and activator protein (AP)-1 in activated mast cells. GPMCs (1 106) pre-incubated with [3H] arachidonic acid (1 mCi) and BMMCs (1 106 cells) were
sensitized and challenged by each antigen/antibody reaction. The experimental details and PPT treatment were as described in Materials and methods. (A) PLA2 activity in GPMCs.
The data are expressed as mean  standard error of the mean (n ¼ 8). ** p < 0.01 versus control (Con). þþ, p < 0.01 versus ovalbumin (OVA) challenge. (B) The expression of PLA2
protein in guinea pig mast cells (GPMCs) or mouse bone marrow-derived mast cells (BMMCs). (C) Expression of COX-1/2 in BMMCs. (D) Activities of transcription factors, NF-kB and
AP-1 in BMMCs. 1) Numbers below the bands indicate the ratio of band intensity of each band versus those of control and actin protein or total protein. (a) Negative control; (b)
competition. The data are representative of four independent experiments (n ¼ 4). HSA-DNP, human serum albuminedinitrophenyl.
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production in combination with the inhibition of PLA2 activity and
the reduction of [Ca2þ]i. This indicates that PPT may concurrently
inhibit the COX-2 and LOX activities, thereby reducing early phase
of allergic responses.
IgE-mediated signaling pathways induce production of inﬂam-
matory cytokines via activation of MAP kinases during activation of
mast cells [32,43,44]. NF-kB and AP-1 are pleiotropic transcription
factors that play an important role in regulating the expression of
multiple genes including Th2 cytokines [20], and allergic inﬂam-
mation is associated with increased NF-kB activity in animal lung
tissues and BAL cells [28,45]. A rise of [Ca2þ]i level also leads to the
activation of MAP kinases and NF-kB, which play important roles in
the control of IgE-mediated cytokine synthesis in mast cells [46e
49]. Our results (Figs. 1C, 2, 3C, 4D) suggest that PPT inhibits pro-
duction of inﬂammatory cytokines via inhibiting an increase ofcellular Ca2þ level, the activities of MAP kinases and NF-kB/AP-1 in
the IgE-mediated activated mast cells. Similarly, ginsenosides have
been reported to inhibit NF-kB activation as well as histamine
release in certain cell lines [7,37]. However, IL-10, which is known
as an anti-inﬂammatory cytokine, was not inhibited in the PPT
pretreatment.
PPT pretreatment exerted antiallergic effects in the same
manner in both types of mast cells when activated by speciﬁc an-
tigen/antibody reaction. It can be inferred that PPT acts via regu-
lating expression of Syk kinase, which is critical for the downstream
propagation of signals in FceRI-mediated mast cell activation,
although further upstream signaling molecules of Syk and [Ca2þ]i
were not deﬁned in this experiment. This can be supported by the
previous reports that a rise of [Ca2þ]i triggered the induction of
activities of cellular signaling molecules such as PKCs, MAP kinases,
PLA2, and NF-kB/AP-1 [18,20,38,39,42,46e49].
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sponses with their characteristic effects. Ginsenosides Rb1, Rg1,
Rg2, and Rc exert antiallergic effects by inhibiting histamine release
from mast cells [7,9,16,17] and antiallergic effects in murine model
[10,13]. In addition, PPT, an intestinal metabolite of ginsenosides
(an aglycone moiety) inhibited the release and production of in-
ﬂammatory mediators (histamine, LTs, and cytokines, respectively)
in the GPMCs as well as in BMMCs, which is compatible with the
observations by other laboratories that ginseng metabolites such as
compound K [16] and Rh2 [17] inhibit release of mediators such as
b-hexosaminidase from RBL-2H3 cells. Thus, the sugar moiety
attached at their triterpenoid structures is not supposed to affect
the mediator release during mast cell activation.
Ginsenoside Re, which induces allergic responses (unpublished
data), exists in very low amounts in ginseng extracts. An allergic
asthma observed in personnel exposed to ginseng for long periods,
such as the workers engaged in Korean ginseng wholesale may be
due to ginsenoside Re [8].
The blood concentration of PPT after oral intake of ginseng
extract would be much lower than that of PPT used in this exper-
iment. Therefore, it can be supposed that the cumulative blood
concentration of ginseng metabolites when taken for longer pe-
riods will be much more close to the concentration of PPT used in
this experiment. Thus, it is necessary to measure the blood con-
centrations of ginseng metabolites after long-term use of ginseng
extract for more appropriately evaluating the dose-dependent ef-
fects of intestinal ginseng metabolites in vivo.
In conclusion, we suggest that PPT, one of the intestinal ginseng
metabolites, inhibits the release and production of inﬂammatory
mediators by affecting the cellular signaling pathways initiated by
Syk activation in the FceRI receptor stimulation and it may be used
as an auxiliary substance for treating allergy-induced asthma.
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